Rebecca Moroose

2.4k total citations · 1 hit paper
23 papers, 1.0k citations indexed

About

Rebecca Moroose is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Rebecca Moroose has authored 23 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Rebecca Moroose's work include HER2/EGFR in Cancer Research (13 papers), Advanced Breast Cancer Therapies (8 papers) and Cancer Treatment and Pharmacology (8 papers). Rebecca Moroose is often cited by papers focused on HER2/EGFR in Cancer Research (13 papers), Advanced Breast Cancer Therapies (8 papers) and Cancer Treatment and Pharmacology (8 papers). Rebecca Moroose collaborates with scholars based in United States, France and United Kingdom. Rebecca Moroose's co-authors include Aditya Bardia, Nikita Shah, Ingrid A. Mayer, Robert M. Sharkey, Linda T. Vahdat, William A. Wegener, David M. Goldenberg, Jennifer R. Diamond, Vandana G. Abramson and Kevin Kalinsky and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Rebecca Moroose

23 papers receiving 1.0k citations

Hit Papers

Sacituzumab Govitecan-hziy in Refractory Metastatic Tripl... 2019 2026 2021 2023 2019 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
    2019 599 citations Aditya Bardia, Ingrid A. Mayer et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rebecca Moroose United States 9 747 357 217 191 190 23 1.0k
Dongsheng Yue China 22 716 1.0× 665 1.9× 112 0.5× 458 2.4× 372 2.0× 69 1.4k
Tatsunori Shimoi Japan 16 775 1.0× 422 1.2× 243 1.1× 229 1.2× 176 0.9× 105 1.2k
Yingjie Shao China 18 589 0.8× 254 0.7× 64 0.3× 286 1.5× 299 1.6× 42 1.0k
B. Nelson United States 7 795 1.1× 278 0.8× 52 0.2× 295 1.5× 84 0.4× 12 1.0k
Claudia Maggi Italy 21 873 1.2× 360 1.0× 172 0.8× 261 1.4× 301 1.6× 36 1.3k
Alexandre Bodmer Switzerland 14 344 0.5× 94 0.3× 105 0.5× 177 0.9× 259 1.4× 49 692
Yunjiang Liu China 13 517 0.7× 235 0.7× 154 0.7× 186 1.0× 188 1.0× 57 813
Esther Zamora Spain 10 756 1.0× 576 1.6× 26 0.1× 203 1.1× 277 1.5× 22 1.0k
Ingo Alldinger Germany 17 530 0.7× 359 1.0× 32 0.1× 354 1.9× 204 1.1× 38 1.0k
Catherine A. Azar United States 10 881 1.2× 215 0.6× 147 0.7× 220 1.2× 362 1.9× 13 1.1k

Countries citing papers authored by Rebecca Moroose

Since Specialization
Citations

This map shows the geographic impact of Rebecca Moroose's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rebecca Moroose with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rebecca Moroose more than expected).

Fields of papers citing papers by Rebecca Moroose

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rebecca Moroose. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rebecca Moroose. The network helps show where Rebecca Moroose may publish in the future.

Co-authorship network of co-authors of Rebecca Moroose

This figure shows the co-authorship network connecting the top 25 collaborators of Rebecca Moroose. A scholar is included among the top collaborators of Rebecca Moroose based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rebecca Moroose. Rebecca Moroose is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Slamon, Dennis J., Daniil Stroyakovskiy, Denise A. Yardley, et al.. (2023). Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial.. Journal of Clinical Oncology. 41(17_suppl). LBA500–LBA500. 82 indexed citations
2.
Cox, Amanda J., Ana Carolina Martini, Rebecca Moroose, et al.. (2022). Chaperonin containing TCP1 as a marker for identification of circulating tumor cells in blood. PLoS ONE. 17(6). e0264651–e0264651. 3 indexed citations
3.
Guo, Cen, Yanke Yu, Jayeta Chakrabarti, et al.. (2022). Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment. British Journal of Clinical Pharmacology. 88(7). 3392–3403. 8 indexed citations
4.
O’Shaughnessy, Joyce, Rebecca Moroose, Sunil Babu, et al.. (2020). Results of ENCORE 602 (TRIO025), a phase II, randomized, placebo-controlled, double-blinded, multicenter study of atezolizumab with or without entinostat in patients with advanced triple-negative breast cancer (aTNBC).. Journal of Clinical Oncology. 38(15_suppl). 1014–1014. 31 indexed citations
5.
Hoffman, Justin, Jayeta Chakrabarti, Anna Plotka, et al.. (2019). Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors. Anti-Cancer Drugs. 30(5). 523–532. 8 indexed citations
6.
Bardia, Aditya, Ingrid A. Mayer, Linda T. Vahdat, et al.. (2019). Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine. 380(8). 741–751. 599 indexed citations breakdown →
7.
8.
Bardia, Aditya, Jennifer R. Diamond, Linda T. Vahdat, et al.. (2018). Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2- metastatic breast cancer (mBC).. Journal of Clinical Oncology. 36(15_suppl). 1004–1004. 16 indexed citations
9.
Kelly, Patrick, Zhe Ma, Said Baidas, et al.. (2017). Patterns of Progression in Metastatic Estrogen Receptor Positive Breast Cancer: An Argument for Local Therapy. International Journal of Breast Cancer. 2017. 1–7. 21 indexed citations
10.
Sharkey, Robert M., Allyson J. Ocean, Alexander Starodub, et al.. (2017). Abstract 3734: Pharmacokinetics of sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) targeting Trop-2, in patients with diverse advanced solid tumors. Cancer Research. 77(13_Supplement). 3734–3734. 4 indexed citations
11.
Bardia, Aditya, Jennifer R. Diamond, Wells A. Messersmith, et al.. (2016). Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.. Journal of Clinical Oncology. 34(18_suppl). LBA509–LBA509. 3 indexed citations
12.
Starodub, Alexander, Allyson J. Ocean, Aditya Bardia, et al.. (2015). Abstract CT236: Advanced solid cancer therapy with a novel antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): key preclinical and clinical results. Cancer Research. 75(15_Supplement). CT236–CT236. 3 indexed citations
13.
14.
Bardia, Aditya, Linda T. Vahdat, Jennifer R. Diamond, et al.. (2015). Therapy of refractory/relapsed metastatic triple-negative breast cancer (TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience.. Journal of Clinical Oncology. 33(15_suppl). 1016–1016. 10 indexed citations
15.
Bardia, Aditya, Ingrid A. Mayer, Jennifer R. Diamond, et al.. (2015). Abstract LB-C16: Safety and tumor responses of the anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in refractory, metastatic, triple-negative breast cancer (TNBC): An ongoing Phase II trial. Molecular Cancer Therapeutics. 14(12_Supplement_2). LB–C16. 1 indexed citations
16.
Saura, Cristina, José Á. García-Sáenz, Binghe Xu, et al.. (2014). Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer. Journal of Clinical Oncology. 32(32). 3626–3633. 103 indexed citations
17.
Hurvitz, Sara A., Heather Allen, Rebecca Moroose, et al.. (2010). A Phase II Trial of Docetaxel With Bevacizumab as First-line Therapy for HER2-Negative Metastatic Breast Cancer (TORI B01). Clinical Breast Cancer. 10(4). 307–312. 7 indexed citations
18.
Francis, John L., et al.. (2004). Successful Use of Bivalirudin in the Treatment of Patients Suspected, or at Risk of, Heparin-Induced Thrombocytopenia.. Blood. 104(11). 4077–4077. 13 indexed citations
19.
Francis, John L., George J. Palmer, Rebecca Moroose, & Alane Drexler. (2003). Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. The Annals of Thoracic Surgery. 75(1). 17–22. 109 indexed citations
20.
Moroose, Rebecca & Leon W. Hoyer. (1986). AND PLATELET FUNCTION. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dongsheng Yue Breakdown of academic impact, for papers by Tatsunori Shimoi Breakdown of academic impact, for papers by Yingjie Shao Breakdown of academic impact, for papers by B. Nelson Breakdown of academic impact, for papers by Claudia Maggi Breakdown of academic impact, for papers by Alexandre Bodmer Breakdown of academic impact, for papers by Yunjiang Liu Breakdown of academic impact, for papers by Esther Zamora Breakdown of academic impact, for papers by Ingo Alldinger Breakdown of academic impact, for papers by Catherine A. Azar
Rankless by CCL
2026